Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)

NCT00272051 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00272051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00272051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2002
Completion date
May 31, 2004
Enrollment
620
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, colorectal neoplasms, metastases